Nuclein, LLC filed an amended Form D with the Securities and Exchange Commission on 2026-10-27.
Nuclein, LLC filed an amended Form D notice of an exempt securities offering with the SEC on October 27, 2026. The filing reports $15.65M sold. Its industry group is Biotechnology. It names Alan Blake (Executive Officer, Director), Richard Crockett (Director), William Cunningham (Director) (SEC Form D/A, October 27, 2026).
In its own words: “DASH™ Rapid PCR System is a simple, affordable, point-of-care platform that performs sample-to-answer PCR in 15 minutes.” (nuclein.com, checked November 1, 2026)
Is this your company?
Sell to companies like Nuclein, LLC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Nuclein, LLC.
Free to see. No signup.
More on the people and the money behind Nuclein, LLC, from the filings we hold.
Biotechnology raises by companies based in Texas, filed within 90 days of this one, largest first.
Get an email when Nuclein, LLC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Nuclein, LLC raises, hires or launches. No email unless you switch it on.
Watch Nuclein, LLC →Get the full cited report on Nuclein, LLC
What the filing shows about Nuclein, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nuclein, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Nuclein, LLC's address as 8305 Cross Park Dr, Austin, TX 78754.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Nuclein, LLC →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Nuclein, LLC is a registered filer with the SEC (CIK 1787352) and has filed since 2023-03-23. 5 filings are on record, the latest on 2026-06-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Nuclein, LLC's Form D of 2026-10-27 names Alan Blake, Richard Crockett, William Cunningham and 5 more as its officers, directors or promoters.
Its new offerings report $2.04M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $15.65M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Alan Blake is named as Executive Officer and Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
Richard Crockett is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
William Cunningham is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
Douglas Bryant is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
Sanjay Chandra is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
H. Shockley is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
Walter Narajowski is named as Director on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
Jeffrey Stukuls is named as Executive Officer on the Form D that Nuclein, LLC filed with the SEC on 27 October 2026, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2026-10-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Nuclein, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nuclein, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nuclein, LLC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Nuclein, LLCYou get an alert in MentionFox the next time this company shows up.
If you're behind Nuclein, LLC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Nuclein, LLC. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nuclein-llc-form-d-000005